These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 34417955)

  • 1. Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.
    Kline KAF; Kallen ME; Duong VH; Law JY
    Curr Hematol Malig Rep; 2021 Oct; 16(5):384-393. PubMed ID: 34417955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.
    Li X; Cao W; Zhang S; Li L; Li Y; Jiang Z; Wan D; Yu J
    Medicine (Baltimore); 2021 Jun; 100(23):e26323. PubMed ID: 34115047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.
    Balsat M; Cacheux V; Carre M; Tavernier-Tardy E; Thomas X
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):879-891. PubMed ID: 33016157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN; Beppu L; Radich JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
    Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E
    Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Short NJ; Kantarjian H; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):61-66. PubMed ID: 34561201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
    Pui CH; Roberts KG; Yang JJ; Mullighan CG
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future management of Ph/BCR-ABL positive ALL.
    Maino E; Sancetta R; Viero P; Imbergamo S; Scattolin AM; Vespignani M; Bassan R
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):723-40. PubMed ID: 24611626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro".
    Bachanova V
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S10-S15. PubMed ID: 28760293
    [No Abstract]   [Full Text] [Related]  

  • 15. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
    Wieduwilt MJ
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.
    Molina JC; Carraway HE
    Curr Treat Options Oncol; 2024 Aug; 25(8):993-1010. PubMed ID: 38916714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
    Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.